Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Diabetic Macular Edema (RESPOND)
NCT01135914Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2010
- Primary completion
- Mar 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Mean Change From Baseline in Best Corrected Visual Acuity at 12 months. Started Jul 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01135914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01135914.